Coupling BOTH UCLA combo trials to DCVax-L

Another source has now corroborated the fact, that ATL-DC used in the UCLA combo trial with poly-iclc, is DCvax-L, there by also proved, that the upcoming Nature pre-print journal regarding this trial has DCVax-L as its center piece.

ATLnsider

1.1K views

I am including some additional evidence below from the journal Personalized Medicine in Oncology™ (PMO), which clearly show that ATL-DC is DCVax-L.

Who is the journal Personalized Medicine in Oncology™ (PMO)? According to their website, PMO is:

Personalized Medicine in Oncology™ (PMO) is a peer-reviewed journal serving the informational needs of oncologists related to precision medicine and the next generation of oncologic care. The goal of PMO is to sensitize practitioners to the performance realities of new diagnostic and treatment discoveries and clarify molecular profiling technology as it relates to diagnostic, prognostic, and predictive medicine.

In the article Vaccines for Glioblastoma PMO wrote this about the ATL-DC (DCVax-L) + poly-ICLC trial starting in 2010, that has been conducted by Dr. Linda Liau and Dr. Robert Prins at UCLA :

Did it just mention a trial with DCVax-L and poly-iclc?

“Also based on the results from the above-mentioned phase 1 study (NCT00068510) in which patients received DCVax-L in conjunction with toll-like receptor agonists, a placebo-controlled phase 2 study (NCT01204684) is under way at Jonsson Comprehensive Cancer Center in Los Angeles by the same investigators to evaluate the vaccine in combination with either 0.2% imiquimod cream, a single intramuscular injection of poly ICLC, or placebo.“

What is Clinical Trial NCT01204684? Here is the Study Description for Clinical Trial NCT01204684:

And where is that clinical trial ALSO mentioned? In the upcoming Nature pre-print article, announced in September 2023.

Did we just prove that DCVax-L is the equivalent of ATL-DC in this combo trial?

Did we just prove that DCVax_L is the center piece of the upcoming Nature pre-print journal?

The head image is from Robert Prins’ latest video showing some of the authors and researchers from the DCVax-L + poly-iclc combo trial.

Now let’s link the UCLA SPORE trial with Keytruda and DCvax-L to the other combo trial with poly-iclc.

Look at the grant number in the image for this article. It is for the UCLA Spore (brain cancer, SPORE 1 project being DCVax-L and Keytruda) 1P50 CA211015. Follow the grant to the Grantome website.